LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article: Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA Cohort.

    Roth, Gaël S / Fayet, Yohan / Benmameche-Medjahed, Sakina / Ducimetière, Françoise / Charreton, Amandine / Cropet, Claire / Chabaud, Sylvie / Marion-Audibert, Anne-Marie / Berthelet, Olivier / Walter, Thomas / Adham, Mustapha / Baconnier, Mathieu / Tavan, David / Williet, Nicolas / Artru, Pascal / Huet-Penz, Floriane / Ray-Coquard, Isabelle / Farsi, Fadila / Labrosse, Hélène /
    de la Fouchardière, Christelle

    Cancers

    2022  Volume 14, Issue 21

    Abstract: Background and aims: Pancreatic cancer is highly lethal and often diagnosed at an advanced stage. This cohort study analyzes the impact of care pathways, delays, and socio-spatial determinants on pancreatic cancer patients’ diagnosis, treatment, and ... ...

    Abstract Background and aims: Pancreatic cancer is highly lethal and often diagnosed at an advanced stage. This cohort study analyzes the impact of care pathways, delays, and socio-spatial determinants on pancreatic cancer patients’ diagnosis, treatment, and prognosis. Method: Patients with pancreatic adenocarcinoma newly diagnosed at all stages between January and June 2016 in the AuRA French region were included. The influence on survival of delays of care, healthcare centers’ expertise, and socio-spatial determinants was evaluated. Results: Here, 538 patients were included in 76 centers including 116 patients (21.8%) with resectable, 64 (12.0%) borderline-resectable, 147 (27.6%) locally-advanced tumors, and 205 (38.5%) with metastatic disease. A delay between first symptoms and CT scans did not statistically influence overall survival (OS). In resected patients, OS was significantly higher in centers with more than 20 surgeries (HR<5 surgeries/year = 2.236 and HR5-20 surgeries/year = 1.215 versus centers with > 20 surgeries/year p = 0.0081). Regarding socio-spatial determinants, patients living in municipalities with greater access to a general practitioner (HR = 1.673, p = 0.0153) or with a population density below 795.1 people/km2 (HR = 1.881, p = 0.0057) were significantly more often resectable. Conclusion: This cohort study supports the pivotal role of general practitioner in cancer care and the importance of the centralization of pancreatic surgery to optimize pancreatic cancer patients’ care and outcomes. However, delays of care did not impact patient survival.
    Language English
    Publishing date 2022-11-03
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14215413
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.

    Gronnier, Caroline / Mariette, Christophe / Lepage, Come / Monterymard, Carole / Jary, Marine / Ferru, Aurélie / Baconnier, Mathieu / Adhoute, Xavier / Tavan, David / Perrier, Hervé / Guerin-Meyer, Véronique / Lecaille, Cédric / Bonichon-Lamichhane, Nathalie / Pillon, Didier / Cojocarasu, Oana / Egreteau, Joëlle / D'journo, Xavier Benoit / Dahan, Laétitia / Locher, Christophe /
    Texereau, Patrick / Collet, Denis / Michel, Pierre / Ben Abdelghani, Meher / Guimbaud, Rosine / Muller, Marie / Bouché, Olivier / Piessen, Guillaume

    Cancers

    2023  Volume 15, Issue 7

    Abstract: Purpose: While perioperative chemotherapy provides a survival benefit over surgery alone in gastric and gastroesophageal junction (G/GEJ) adenocarcinomas, the results need to be improved. This study aimed to evaluate the efficacy and safety of ... ...

    Abstract Purpose: While perioperative chemotherapy provides a survival benefit over surgery alone in gastric and gastroesophageal junction (G/GEJ) adenocarcinomas, the results need to be improved. This study aimed to evaluate the efficacy and safety of perioperative cetuximab combined with 5-fluorouracil and cisplatin.
    Patients and methods: Patients received six cycles of cetuximab, cisplatin, and simplified LV5FU2 before and after surgery. The primary objective was a combined evaluation of the tumor objective response (TOR), assessed by computed tomography, and the absence of major toxicities resulting in discontinuation of neoadjuvant chemotherapy (NCT) (45% and 90%, respectively).
    Results: From 2011 to 2013, 65 patients were enrolled. From 64 patients evaluable for the primary endpoint, 19 (29.7%) had a morphological TOR and 61 (95.3%) did not stop NCT prematurely due to major toxicity. Sixty patients (92.3%) underwent resection. Sixteen patients (/56 available, 28.5%) had histological responses (Mandard tumor regression grade ≤3). After a median follow-up of 44.5 months, median disease-free and overall survival were 24.4 [95% CI: 16.4-39.4] and 40.3 months [95% CI: 27.5-NA], respectively.
    Conclusion: Adding cetuximab to the NCT regimen in operable G/GEJ adenocarcinomas is safe, but did not show enough efficacy in the present study to meet the primary endpoint (NCT01360086).
    Language English
    Publishing date 2023-04-06
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15072188
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients' Profiles With Oxaliplatin-Induced Peripheral Neuropathy.

    Kerckhove, Nicolas / Selvy, Marie / Lambert, Céline / Gonneau, Coralie / Feydel, Gabrielle / Pétorin, Caroline / Vimal-Baguet, Agnès / Melnikov, Sergey / Kullab, Sharif / Hebbar, Mohamed / Bouché, Olivier / Slimano, Florian / Bourgeois, Vincent / Lebrun-Ly, Valérie / Thuillier, Frédéric / Mazard, Thibault / Tavan, David / Benmammar, Kheir Eddine / Monange, Brigitte /
    Ramdani, Mohamed / Péré-Vergé, Denis / Huet-Penz, Floriane / Bedjaoui, Ahmed / Genty, Florent / Leyronnas, Cécile / Busserolles, Jérôme / Trévis, Sophie / Pinon, Vincent / Pezet, Denis / Balayssac, David

    Frontiers in pharmacology

    2021  Volume 12, Page(s) 744085

    Abstract: Oxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in ... ...

    Abstract Oxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in colorectal cancer survivors, a secondary analysis was designed to explore the possibility that different clusters of patients may co-exist among a cohort of patients with oxaliplatin-related CIPN. Other objectives were to characterize these clusters considering CIPN severity, anxiety, depression, health-related quality of life (HRQOL), patients' characteristics and oxaliplatin treatments. Among the 96 patients analyzed, three clusters were identified (cluster 1: 52, cluster 2: 34, and cluster 3: 10 patients). Clusters were significantly different according to CIPN severity and the proportion of neuropathic pain (cluster 1: low, cluster 2: intermediate, and cluster 3: high). Anxiety, depressive disorders and HRQOL alteration were lower in cluster 1 in comparison to clusters 2 and 3, but not different between clusters 2 and 3. This study underlines that patients with CIPN are not a homogenous group, and that CIPN severity is associated with psychological distress and a decline of HRQOL. Further studies are needed to explore the relation between clusters and CIPN management.
    Language English
    Publishing date 2021-11-04
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2021.744085
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study.

    Selvy, Marie / Pereira, Bruno / Kerckhove, Nicolas / Gonneau, Coralie / Feydel, Gabrielle / Pétorin, Caroline / Vimal-Baguet, Agnès / Melnikov, Sergey / Kullab, Sharif / Hebbar, Mohamed / Bouché, Olivier / Slimano, Florian / Bourgeois, Vincent / Lebrun-Ly, Valérie / Thuillier, Frédéric / Mazard, Thibault / Tavan, David / Benmammar, Kheir Eddine / Monange, Brigitte /
    Ramdani, Mohamed / Péré-Vergé, Denis / Huet-Penz, Floriane / Bedjaoui, Ahmed / Genty, Florent / Leyronnas, Cécile / Busserolles, Jérôme / Trevis, Sophie / Pinon, Vincent / Pezet, Denis / Balayssac, David

    Journal of clinical medicine

    2020  Volume 9, Issue 8

    Abstract: 1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer ... ...

    Abstract (1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer survivors is made up of survivors of colorectal cancer. (2) Methods: A multicenter, cross-sectional study was conducted in 16 French centers to assess the prevalence of CIPN, as well as its consequences (neuropathic pain, anxiety, depression, and quality of life) in cancer survivors during the 5 years after the end of adjuvant oxaliplatin chemotherapy. (3) Results: Out of 406 patients, the prevalence of CIPN was 31.3% (95% confidence interval: 26.8-36.0). Little improvement in CIPN was found over the 5 years, and 36.5% of patients with CIPN also had neuropathic pain. CIPN was associated with anxiety, depression, and deterioration of quality of life. None of the patients with CIPN were treated with duloxetine (recommendation from American Society of Clinical Oncology), and only 3.2%, 1.6%, and 1.6% were treated with pregabalin, gabapentin, and amitriptyline, respectively. (4) Conclusions: Five years after the end of chemotherapy, a quarter of patients suffered from CIPN. The present study showed marked psychological distress and uncovered a failure in management in these patients.
    Language English
    Publishing date 2020-07-27
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm9082400
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Eruption vésiculo-pustuleuse et maladie de Crohn.

    Baty, Vincent / Rocca, Pierre / Tavan, David / Koeb, Marie-Hélène / Bory, Roger-Michel

    Gastroenterologie clinique et biologique

    2002  Volume 26, Issue 3, Page(s) 293–295

    Title translation Vesiculo-pustular eruption and Crohn's disease.
    MeSH term(s) Adult ; Crohn Disease/complications ; Crohn Disease/diagnosis ; Diagnosis, Differential ; Female ; Humans ; Sweet Syndrome/complications ; Sweet Syndrome/diagnosis ; Sweet Syndrome/pathology
    Language French
    Publishing date 2002-03
    Publishing country France
    Document type Case Reports ; Journal Article
    ZDB-ID 752002-5
    ISSN 0399-8320
    ISSN 0399-8320
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1346: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 19: Show issues
    Zs.MN 1: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer.

    de la Fouchardière, Christelle / Négrier, Sylvie / Labrosse, Hugues / Martel Lafay, Isabelle / Desseigne, Françoise / Méeus, Pierre / Tavan, David / Petit-Laurent, Fabien / Rivoire, Michel / Pérol, David / Carrie, Christian

    International journal of radiation oncology, biology, physics

    2010  Volume 77, Issue 2, Page(s) 409–413

    Abstract: Purpose: The study aimed to determine the maximum tolerated dose of daily irinotecan given with concomitant radiotherapy in patients with locally advanced adenocarcinoma of the pancreas.: Methods and materials: Between September 2000 and March 2008, ... ...

    Abstract Purpose: The study aimed to determine the maximum tolerated dose of daily irinotecan given with concomitant radiotherapy in patients with locally advanced adenocarcinoma of the pancreas.
    Methods and materials: Between September 2000 and March 2008, 36 patients with histologically proven unresectable pancreas adenocarcinoma were studied prospectively. Irinotecan was administered daily, 1 to 2 h before irradiation. Doses were started at 6 mg/m(2) per day and then escalated by increments of 2 mg/m(2) every 3 patients. Radiotherapy was administered in 2-Gy fractions, 5 fractions per week, up to a total dose of 50 Gy to the tumor volume. Inoperability was confirmed by a surgeon involved in a multidisciplinary team. All images and responses were centrally reviewed by radiologists.
    Results: Thirty-six patients were enrolled over a period of 8 years through eight dose levels (6 mg/m(2) to 20 mg/m(2) per day). The maximum tolerated dose was determined to be 18 mg/m(2) per day. The dose-limiting toxicities were nausea/vomiting, diarrhea, anorexia, dehydration, and hypokalemia. The median survival time was 12.6 months with a median follow-up of 53.8 months. The median progression-free survival time was 6.5 months, and 4 patients (11.4%) with very good responses could undergo surgery.
    Conclusions: The maximum tolerated dose of irinotecan is 18 mg/m(2) per day for 5 weeks. Dose-limiting toxicities are mainly gastrointestinal. Even though efficacy was not the aim of this study, the results are very promising, with a median survival time of 12.6 months.
    MeSH term(s) Adenocarcinoma/pathology ; Adenocarcinoma/radiotherapy ; Adult ; Aged ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives ; Disease Progression ; Drug Administration Schedule ; Feasibility Studies ; Female ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Pancreatic Neoplasms/mortality ; Pancreatic Neoplasms/pathology ; Pancreatic Neoplasms/radiotherapy ; Pancreatic Neoplasms/surgery ; Prospective Studies ; Radiation-Sensitizing Agents/administration & dosage ; Radiation-Sensitizing Agents/adverse effects ; Survival Analysis
    Chemical Substances Radiation-Sensitizing Agents ; irinotecan (7673326042) ; Camptothecin (XT3Z54Z28A)
    Language English
    Publishing date 2010-06-01
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 197614-x
    ISSN 1879-355X ; 0360-3016
    ISSN (online) 1879-355X
    ISSN 0360-3016
    DOI 10.1016/j.ijrobp.2009.05.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1218: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top